Quality control of commercial tablets containing the novel antipsychotic quetiapine

Journal of Pharmaceutical and Biomedical Analysis

Volumn 32, Issue 4-5, 2003, Pages 1037-1044

  Pucci, Vincenzo ^a   Mandrioli, Roberto ^a   Ferranti, Anna ^a   Furlanetto, Sandra ^b   Raggi, Maria Augusta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

CZE; Quality control; Quetiapine; Spectrophotometry; Tablets

Indexed keywords

AMITRIPTYLINE; BUFFER; CHLORPROMAZINE; DIBENZEPIN; ELECTROLYTE; LOXAPINE; MAPROTILINE; NEUROLEPTIC AGENT; PAROXETINE; PHOSPHATE; PROTRIPTYLINE; QUETIAPINE; TRIPROLIDINE;

ACIDITY; ANALYTIC METHOD; CAPILLARY ZONE ELECTROPHORESIS; COMPARATIVE STUDY; CONFERENCE PAPER; DRUG FORMULATION; DRUG QUALITY; PRIORITY JOURNAL; SEPARATION TECHNIQUE; SPECTRAL SENSITIVITY; SPECTROPHOTOMETRY; TABLET;

EID: 0041623006     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(03)00206-1     Document Type: Conference Paper

References (25)

1. Weiden P.J. J. Prac. Psych. Behav. Health. 3:1997;368-374.
2. Small J.G., Hirsch S.R., Arvantis L.A., Miller B.G., Link C.G.G. Arch. Gen. Psychiatry. 54:1997;549-557.
3. Worrel J.A., Marken P.A., Beckman S.E., Ruether V.L. Am. J. Health-Syst. Pharm. 57:2000;238-255.
4. Gefvert O., Bergstrom M., Langstrom B., Lundberg T., Lindstrom L., Yates R. Psychopharmacology. 135:1998;119-126.
5. Goldstein J.M. Drugs Today. 35:1999;193-210.
6. Meats P. Int. J. Psychiatry Clin. Pract. 1:1997;231-239.
7. Kasper S., Muller-Spahn F. Expert. Opin. Pharmacother. 1:2000;783-801.
8. Prior T.I., Chue P.S., Tibbo P., Baker G.B. Eur. Neuropsychopharmacol. 9:1999;301-309.
9. C.F. Caley, S. Rosenbaum, Formulary 33 (1998) 105-106, 109-110, 112, 115-116, 119.
10. Dev V., Raniwalla J. Drug Saf. 23:2000;295-307.
11. Arvanitis L.A., Miller B.G. Biol. Psychiatry. 42:1997;233-246.
12. Goldstein J.M., Arvanitis L.A. CNS Drug Rev. 1:1995;50-73.
13. M.A. Raggi, Current Medicinal Chemistry 9 (2002) 1397-1409.
14. Gunasekara N.S., Spencer C.M. CNS Drugs. 9:1998;325-340.
15. Casey D.E. J. Clin. Psychiatry. 58:1997;55-62.
16. Pollak P., Zbuk K. Clin. Pharmacol. Ther. 68:2000;92-97.
17. Anderson D.T., Friz L.K. J. Anal. Toxicol. 24:2000;300-304.
18. Davis P.C., Wong J., Gefvert O. J. Pharm. Biomed. Anal. 20:1999;271-282.
19. Raggi M.A., Fanali S., Mandrioli R., Bugamelli F., Volterra V. J. Pharm. Biomed. Anal. 30:2002;969-977.
20. Pucci V., Raggi M.A., Kenndler E. J. Liq. Chromatogr. R.T. 23:2000;25-34.
21. Raggi M.A., Casamenti G., Mandrioli R., Izzo G., Kenndler E. J. Pharm. Biomed. Anal. 23:2000;973-981.
22. Raggi M.A., Pucci V., Bugamelli F., Volterra V. J. AOAC Int. 84:2001;361-367.
23. Raggi M.A., Bugamelli F., Casamenti G., Giovanninetti G., Volterra V. Pharmazie. 53:1998;452-455.
24. Raggi M.A., Casamenti G., Mandrioli R., Sabbioni C., Volterra V. J. Pharm. Biomed. Anal. 23:2000;161-167.
25. United States Pharmacopeia 24th Ed., pp. 304-305, 2150-2151, 2000-2002. United States Pharmacopeial Convention, Rockville, MD (2000).